Lagreula Juliette, de Timary Philippe, Elens Laure, Dalleur Olivia
Clinical Pharmacy Research Group (CLIP), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain, Avenue Mounier 72, 1200 Brussels, Belgium.
Fonds de la Recherche Scientifique (FNRS), Brussels, Belgium.
Ther Adv Psychopharmacol. 2022 Aug 23;12:20451253221112587. doi: 10.1177/20451253221112587. eCollection 2022.
Antipsychotic polypharmacy (APP) prescribing and clozapine underuse are considered inappropriate prescribing in schizophrenia. Psychiatric hospitalisations may be suitable occasions to re-evaluate patient pharmacotherapy and to switch to monotherapy.
To explore the evolution of APP and other psychotropic prescribing patterns during psychiatric hospitalisations, to detect characteristics associated with APP on admission and at discharge, and to examine clozapine prescribing patterns.
We performed a retrospective observational study based on electronic health records.
Data on adult inpatients diagnosed with schizophrenia spectrum disorders were collected retrospectively from 6 Belgian hospitals in 2020-2021.
Of the 516 patients included, APP prescribing increased significantly from 47.9% on hospital admission to 59.1% at discharge. On admission and at discharge, APP was associated with prior clozapine use (OR = 2.53, CI = 1.1-5.84, OR = 11.01, CI = 4.45-27.28), treatment with a first-generation antipsychotic (OR = 26.79, CI = 13.08-54.86, OR = 25.2, CI = 12.2-52.04), increased antipsychotic exposure (OR = 8.93, CI = 5.13-15.56, OR = 19.89, CI = 10-39.54), and a greater number of hypno-sedatives (OR = 1.88, CI = 1.23-2.88, OR = 4.18, CI = 2.53-6.91). APP was negatively associated with involuntary admission (OR = 0.31, CI = 0.14-0.7, OR = 0.3, CI = 0.13-0.68). When using an alternative definition of monotherapy (i.e. including patients with an add-on low-dose antipsychotic for sleep disorders), alcohol use disorder (OR = 0.26, CI = 0.13-0.54) and higher age (OR = 0.53, CI = 0.29-0.95) were negatively associated with APP, and living in a residential facility (OR = 2.39 CI = 1.21-4.71) and a higher daily dosage of benzodiazepines during the stay (OR = 1.32 CI = 1.03-1.69) increased the odds of being discharged on APP. On admission, 9.3% of patients were being treated with clozapine. Although 28.1% of patients were eligible for clozapine treatment, only 11% of patients were discharged with a clozapine prescription. For 7 of the 10 patients with a new clozapine prescription, it was directly prescribed in combination with another antipsychotic, without a prior trial of clozapine monotherapy.
Suboptimal prescriptions of antipsychotics in patients with schizophrenia persist after psychiatric hospitalisations and are associated with identifiable characteristics.
在精神分裂症治疗中,联合使用多种抗精神病药物(APP)及氯氮平使用不足被视为不恰当的处方行为。精神病住院治疗可能是重新评估患者药物治疗方案并转为单一疗法的合适时机。
探讨精神病住院期间APP及其他精神药物处方模式的演变,确定入院时和出院时与APP相关的特征,并研究氯氮平的处方模式。
我们基于电子健康记录进行了一项回顾性观察研究。
回顾性收集了2020 - 2021年比利时6家医院诊断为精神分裂症谱系障碍的成年住院患者的数据。
在纳入的516例患者中,APP处方从入院时的47.9%显著增加至出院时的59.1%。入院时和出院时,APP与先前使用氯氮平(比值比[OR]=2.53,可信区间[CI]=1.1 - 5.84;OR = 11.01,CI = 4.45 - 27.28)、使用第一代抗精神病药物治疗(OR = 26.79,CI = 13.08 - 54.86;OR = 25.2,CI = 12.2 - 52.04)、抗精神病药物暴露增加(OR = 8.93,CI = 5.13 - 15.56;OR = 19.89,CI = 10 - 39.54)以及更多的催眠镇静药物(OR = 1.88,CI = 1.23 - 2.88;OR = 4.18,CI = 2.53 - 6.91)相关。APP与非自愿入院呈负相关(OR = 0.31,CI = 0.14 - 0.7;OR = 0.3,CI = 0.13 - 0.68)。当采用单一疗法的另一种定义(即包括为睡眠障碍添加低剂量抗精神病药物的患者)时,酒精使用障碍(OR = 0.26,CI = 0.13 - 0.54)和较高年龄(OR = 0.53,CI = 0.29 - 0.95)与APP呈负相关,居住在寄宿机构(OR = 2.39,CI = 1.21 - 4.71)以及住院期间较高的苯二氮䓬类药物每日剂量(OR = 1.32,CI = 1.03 - 1.69)增加了出院时使用APP的几率。入院时,9.3%的患者接受氯氮平治疗。尽管28.1%的患者符合氯氮平治疗条件,但只有11%的患者出院时开具了氯氮平处方。在10例新开具氯氮平处方的患者中,有7例直接与另一种抗精神病药物联合开具,未先进行氯氮平单一疗法试验。
精神分裂症患者抗精神病药物的处方在精神病住院后仍不理想,并与可识别的特征相关。